MorphoSys Other Current Liab vs Accounts Payable Analysis

MOR Stock

USD 18.39 0.03 0.16%

MorphoSys financial indicator trend analysis is infinitely more than just investigating MorphoSys AG ADR recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether MorphoSys AG ADR is a good investment. Please check the relationship between MorphoSys Other Current Liab and its Accounts Payable accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in MorphoSys AG ADR. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in persons.

Other Current Liab vs Accounts Payable

Other Current Liab vs Accounts Payable Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of MorphoSys AG ADR Other Current Liab account and Accounts Payable. At this time, the significance of the direction appears to have strong relationship.

The correlation between MorphoSys' Other Current Liab and Accounts Payable is 0.77. Overlapping area represents the amount of variation of Other Current Liab that can explain the historical movement of Accounts Payable in the same time period over historical financial statements of MorphoSys AG ADR, assuming nothing else is changed. The correlation between historical values of MorphoSys' Other Current Liab and Accounts Payable is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Other Current Liab of MorphoSys AG ADR are associated (or correlated) with its Accounts Payable. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Accounts Payable has no effect on the direction of Other Current Liab i.e., MorphoSys' Other Current Liab and Accounts Payable go up and down completely randomly.

Correlation Coefficient

0.77

Relationship Direction	Positive
Relationship Strength	Significant

View All Relationships

Other Current Liab

Accounts Payable

An accounting item on the balance sheet that represents MorphoSys obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of MorphoSys AG ADR are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.

Most indicators from MorphoSys' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into MorphoSys AG ADR current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in MorphoSys AG ADR. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in persons.

At this time, MorphoSys' Selling General Administrative is relatively stable compared to the past year. As of 06/01/2024, Sales General And Administrative To Revenue is likely to grow to 0.38, though Tax Provision is likely to grow to (1.1 M).

	2021	2022	2023	2024 (projected)
Interest Expense	181.5M	116.5M	109.9M	115.4M
Depreciation And Amortization	98.4M	10.5M	10.5M	10.4M

Interest Expense Depreciation And Amortization

MorphoSys fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Intangible Assets	Common Stock	Other Assets	Net Receivables	Inventory	Short Long Term Debt Total
Total Assets		0.98	0.99	-0.24	0.82	0.7	-0.89	0.82	0.76	0.97	-0.03	0.93	0.71	0.66	0.98	-0.23	0.9	0.98	0.95	0.94	0.92	0.75	0.59	0.09	0.76	0.88
Other Current Liab	0.98		0.99	-0.36	0.78	0.75	-0.92	0.77	0.76	0.97	0.04	0.9	0.64	0.57	0.98	-0.2	0.87	0.98	0.94	0.89	0.93	0.67	0.51	-0.03	0.82	0.92
Total Current Liabilities	0.99	0.99		-0.3	0.78	0.76	-0.92	0.79	0.74	0.97	-0.01	0.92	0.7	0.63	0.98	-0.22	0.9	0.99	0.93	0.92	0.93	0.73	0.54	0.04	0.82	0.92
Total Stockholder Equity	-0.24	-0.36	-0.3		0.08	-0.4	0.53	0.0	-0.26	-0.43	0.15	0.05	0.21	0.35	-0.42	-0.12	-0.06	-0.41	-0.17	0.05	-0.55	0.18	0.24	0.32	-0.58	-0.43
Property Plant And Equipment Net	0.82	0.78	0.78	0.08		0.32	-0.52	0.91	0.67	0.7	-0.01	0.9	0.45	0.58	0.75	-0.06	0.62	0.75	0.93	0.9	0.59	0.5	0.77	0.1	0.3	0.53
Net Debt	0.7	0.75	0.76	-0.4	0.32		-0.79	0.44	0.25	0.72	-0.1	0.61	0.55	0.33	0.72	-0.16	0.73	0.73	0.54	0.6	0.7	0.55	0.34	-0.17	0.91	0.92
Retained Earnings	-0.89	-0.92	-0.92	0.53	-0.52	-0.79		-0.57	-0.7	-0.95	-0.07	-0.72	-0.67	-0.54	-0.93	0.24	-0.88	-0.93	-0.78	-0.72	-0.96	-0.69	-0.25	0.09	-0.92	-0.93
Accounts Payable	0.82	0.77	0.79	0.0	0.91	0.44	-0.57		0.49	0.75	0.02	0.85	0.49	0.58	0.77	0.1	0.64	0.77	0.89	0.84	0.63	0.53	0.87	-0.03	0.37	0.56
Cash	0.76	0.76	0.74	-0.26	0.67	0.25	-0.7	0.49		0.75	0.0	0.66	0.53	0.55	0.76	-0.21	0.64	0.76	0.76	0.7	0.76	0.57	0.12	0.22	0.53	0.6
Non Current Assets Total	0.97	0.97	0.97	-0.43	0.7	0.72	-0.95	0.75	0.75		-0.02	0.83	0.65	0.57	0.99	-0.2	0.86	0.99	0.89	0.84	0.98	0.69	0.47	0.02	0.83	0.89
Non Currrent Assets Other	-0.03	0.04	-0.01	0.15	-0.01	-0.1	-0.07	0.02	0.0	-0.02		0.0	0.2	0.27	-0.06	-0.15	0.18	-0.06	0.13	-0.05	-0.06	0.2	-0.07	-0.23	-0.12	-0.08
Cash And Short Term Investments	0.93	0.9	0.92	0.05	0.9	0.61	-0.72	0.85	0.66	0.83	0.0		0.7	0.71	0.86	-0.24	0.86	0.87	0.93	0.99	0.72	0.73	0.71	0.07	0.58	0.77
Common Stock Total Equity	0.71	0.64	0.7	0.21	0.45	0.55	-0.67	0.49	0.53	0.65	0.2	0.7		0.94	0.62	-0.35	0.9	0.63	0.59	0.72	0.6	1.0	0.3	0.22	0.59	0.66
Common Stock Shares Outstanding	0.66	0.57	0.63	0.35	0.58	0.33	-0.54	0.58	0.55	0.57	0.27	0.71	0.94		0.55	-0.29	0.8	0.56	0.63	0.73	0.5	0.94	0.41	0.22	0.37	0.49
Non Current Liabilities Total	0.98	0.98	0.98	-0.42	0.75	0.72	-0.93	0.77	0.76	0.99	-0.06	0.86	0.62	0.55		-0.19	0.84	1.0	0.92	0.87	0.97	0.66	0.51	0.03	0.82	0.9
Other Current Assets	-0.23	-0.2	-0.22	-0.12	-0.06	-0.16	0.24	0.1	-0.21	-0.2	-0.15	-0.24	-0.35	-0.29	-0.19		-0.35	-0.19	-0.15	-0.25	-0.2	-0.34	0.02	-0.37	-0.18	-0.22
Other Stockholder Equity	0.9	0.87	0.9	-0.06	0.62	0.73	-0.88	0.64	0.64	0.86	0.18	0.86	0.9	0.8	0.84	-0.35		0.85	0.8	0.85	0.81	0.91	0.42	0.05	0.77	0.86
Total Liab	0.98	0.98	0.99	-0.41	0.75	0.73	-0.93	0.77	0.76	0.99	-0.06	0.87	0.63	0.56	1.0	-0.19	0.85		0.92	0.88	0.97	0.67	0.51	0.03	0.82	0.9
Property Plant And Equipment Gross	0.95	0.94	0.93	-0.17	0.93	0.54	-0.78	0.89	0.76	0.89	0.13	0.93	0.59	0.63	0.92	-0.15	0.8	0.92		0.93	0.82	0.63	0.66	0.03	0.58	0.75
Total Current Assets	0.94	0.89	0.92	0.05	0.9	0.6	-0.72	0.84	0.7	0.84	-0.05	0.99	0.72	0.73	0.87	-0.25	0.85	0.88	0.93		0.74	0.75	0.69	0.19	0.59	0.77
Intangible Assets	0.92	0.93	0.93	-0.55	0.59	0.7	-0.96	0.63	0.76	0.98	-0.06	0.72	0.6	0.5	0.97	-0.2	0.81	0.97	0.82	0.74		0.64	0.33	0.02	0.86	0.88
Common Stock	0.75	0.67	0.73	0.18	0.5	0.55	-0.69	0.53	0.57	0.69	0.2	0.73	1.0	0.94	0.66	-0.34	0.91	0.67	0.63	0.75	0.64		0.33	0.23	0.6	0.68
Other Assets	0.59	0.51	0.54	0.24	0.77	0.34	-0.25	0.87	0.12	0.47	-0.07	0.71	0.3	0.41	0.51	0.02	0.42	0.51	0.66	0.69	0.33	0.33		0.06	0.12	0.32
Net Receivables	0.09	-0.03	0.04	0.32	0.1	-0.17	0.09	-0.03	0.22	0.02	-0.23	0.07	0.22	0.22	0.03	-0.37	0.05	0.03	0.03	0.19	0.02	0.23	0.06		-0.08	-0.06
Inventory	0.76	0.82	0.82	-0.58	0.3	0.91	-0.92	0.37	0.53	0.83	-0.12	0.58	0.59	0.37	0.82	-0.18	0.77	0.82	0.58	0.59	0.86	0.6	0.12	-0.08		0.96
Short Long Term Debt Total	0.88	0.92	0.92	-0.43	0.53	0.92	-0.93	0.56	0.6	0.89	-0.08	0.77	0.66	0.49	0.9	-0.22	0.86	0.9	0.75	0.77	0.88	0.68	0.32	-0.06	0.96

Click cells to compare fundamentals

MorphoSys Account Relationship Matchups

MorphoSys fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	496.4M	1.7B	2.6B	2.4B	2.0B	2.1B
Other Current Liab	46.8M	146.9M	206.9M	230.2M	202.4M	212.5M
Total Current Liabilities	61.6M	200.5M	284.5M	278.3M	264.3M	277.5M
Total Stockholder Equity	394.7M	621.3M	244.9M	157.4M	49.0M	46.6M
Property Plant And Equipment Net	4.7M	50.7M	49.6M	51.0M	15.0M	11.8M
Net Debt	(1.7M)	208.4M	202.5M	(62.9M)	477.4M	501.3M
Retained Earnings	(255.8M)	(157.9M)	(672.3M)	(823.4M)	(1.0B)	(962.5M)
Accounts Payable	10.7M	47.6M	73.8M	38.6M	28.4M	14.7M
Cash	44.3M	109.8M	123.2M	402.4M	158.5M	166.4M
Non Current Assets Total	192.7M	452.7M	1.4B	1.3B	1.2B	1.3B
Non Currrent Assets Other	44.1M	1.6M	4.1M	8.7M	1.2M	1.2M
Cash And Short Term Investments	272.5M	1.1B	993.7M	907.2M	682.8M	716.9M
Common Stock Total Equity	29.4M	31.8M	32.0M	32.9M	37.8M	34.8M
Common Stock Shares Outstanding	126.4M	132.7M	133.6M	136.6M	137.3M	108.5M
Liabilities And Stockholders Equity	496.4M	1.7B	2.6B	2.4B	2.0B	2.1B
Non Current Liabilities Total	40.2M	837.7M	2.0B	2.0B	1.7B	1.8B
Other Current Assets	(40.3K)	10.0M	15.9M	(367.0)	24.0	22.8
Other Stockholder Equity	619.8M	744.1M	830.2M	831.3M	936.1M	982.9M
Total Liab	101.7M	1.0B	2.3B	2.2B	2.0B	2.1B
Property Plant And Equipment Gross	20.8M	50.7M	69.9M	71.5M	37.7M	39.6M
Total Current Assets	303.7M	1.2B	1.1B	1.1B	814.0M	854.7M
Intangible Assets	41.1M	69.4M	838.3M	886.6M	844.1M	886.3M
Common Stock	31.8M	32.0M	32.9M	34.2M	37.7M	35.4M
Other Assets	1.1M	134.4M	199.8M	8.7M	10.0M	9.5M
Net Receivables	20.3M	89.8M	85.8M	112.4M	42.7M	83.8M
Inventory	288.2K	10.0M	20.8M	24.3M	62.1M	65.2M
Short Long Term Debt Total	42.6M	318.2M	325.8M	339.5M	635.9M	667.7M
Good Will	3.7M	1.6M	335.6M	356.2M	342.3M	359.4M
Accumulated Other Comprehensive Income	(1.3M)	2.2M	52.8M	115.3M	88.4M	92.9M
Current Deferred Revenue	1.6M	2.5M	223.9K	19.4M	17.5M	18.4M
Short Term Investments	228.2M	980.5M	870.4M	504.8M	524.3M	372.9M
Short Term Debt	2.5M	3.5M	3.7M	9.6M	14.1M	14.2M
Other Liab	138.1K	523.0M	1.7B	1.6B	1.9B	2.0B
Net Tangible Assets	349.9M	550.3M	(929.0M)	(1.1B)	(976.9M)	(928.0M)
Long Term Debt	0.0	272.8M	282.8M	291.6M	613.1M	643.7M
Long Term Investments	96.0M	99.0M	196.6M	5.4M	3.6M	3.4M
Property Plant Equipment	47.8M	50.7M	49.6M	51.0M	58.6M	61.6M
Capital Lease Obligations	42.6M	45.0M	42.6M	45.8M	12.4M	23.0M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether MorphoSys AG ADR is a strong investment it is important to analyze MorphoSys' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact MorphoSys' future performance. For an informed investment choice regarding MorphoSys Stock, refer to the following important reports:

How To Invest In MorphoSys

Details

Is MorphoSys Stock a good investment?

Details

What is MorphoSys' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in MorphoSys AG ADR. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in persons.

You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.

Complementary Tools for MorphoSys Stock analysis

When running MorphoSys' price analysis, check to measure MorphoSys' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MorphoSys is operating at the current time. Most of MorphoSys' value examination focuses on studying past and present price action to predict the probability of MorphoSys' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MorphoSys' price. Additionally, you may evaluate how the addition of MorphoSys to your portfolios can decrease your overall portfolio volatility.

	Bonds Directory Find actively traded corporate debentures issued by US companies
	Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
	Global Correlations Find global opportunities by holding instruments from different markets
	Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk
	Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios
	Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes

Is MorphoSys' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of MorphoSys. If investors know MorphoSys will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about MorphoSys listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

(0.87)

Earnings Share

(1.49)

Revenue Per Share

1.7163

Quarterly Revenue Growth

0.131

Return On Assets

(0.14)

The market value of MorphoSys AG ADR is measured differently than its book value, which is the value of MorphoSys that is recorded on the company's balance sheet. Investors also form their own opinion of MorphoSys' value that differs from its market value or its book value, called intrinsic value, which is MorphoSys' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because MorphoSys' market value can be influenced by many factors that don't directly affect MorphoSys' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between MorphoSys' value and its price as these two are different measures arrived at by different means. Investors typically determine if MorphoSys is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, MorphoSys' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

MorphoSys Other Current Liab vs Accounts Payable Analysis

Other Current Liab vs Accounts Payable

Other Current Liab vs Accounts Payable Correlation Analysis

Correlation Coefficient

Other Current Liab

Accounts Payable

MorphoSys fundamental ratios Correlations

MorphoSys Account Relationship Matchups

High Positive Relationship

High Negative Relationship

MorphoSys fundamental ratios Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

Complementary Tools for MorphoSys Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Common Stock	+ 1.0	Common Stock Total Equity
Total Liab	+ 1.0	Non Current Liabilities Total
Total Current Liabilities	+ 0.99	Total Assets
Total Current Liabilities	+ 0.99	Other Current Liab
Total Liab	+ 0.99	Total Current Liabilities
Non Current Liabilities Total	+ 0.99	Non Current Assets Total

Intangible Assets	- 0.96	Retained Earnings
Non Current Assets Total	- 0.95	Retained Earnings
Short Long Term Debt Total	- 0.93	Retained Earnings
Total Liab	- 0.93	Retained Earnings
Non Current Liabilities Total	- 0.93	Retained Earnings
Inventory	- 0.92	Retained Earnings